Trial Profile
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 20 Jun 2022 Status changed from recruiting to completed.
- 31 Jul 2018 Planned number of patients changed from 3000 to 100.
- 31 Jul 2018 Status changed from not yet recruiting to recruiting.